



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Recognising the potential of large animals for modelling neuromuscular junction physiology and disease

Citation for published version:

Cahalan, SD, Boehm, I, Jones, R & Piercy, R 2022, 'Recognising the potential of large animals for modelling neuromuscular junction physiology and disease', *Journal of Anatomy*.
<https://doi.org/10.1111/joa.13749>

Digital Object Identifier (DOI):

[10.1111/joa.13749](https://doi.org/10.1111/joa.13749)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of Anatomy

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 Recognising the potential of large animals for modelling neuromuscular junction
2 physiology and disease

3

4 Stephen D. Cahalan*¹, Ines Boehm*^{2,3,4}, Ross A. Jones^{2,3}, Richard J. Piercy¹

5 *both authors contributed equally

6

7 Affiliations:

8 1. Comparative Neuromuscular Diseases Laboratory, Department of Clinical Science
9 and Services, Royal Veterinary College, University of London, London, UK

10 2. Edinburgh Medical School: Biomedical Sciences, University of Edinburgh,
11 Edinburgh, UK

12 3. Euan MacDonald Centre for Motor Neurone Disease Research, University of
13 Edinburgh, Edinburgh, UK

14 4. Biozentrum, University of Basel, Basel, Switzerland (present address)

15

16

17 Correspondence:

18 Richard J. Piercy, Royal Veterinary College, University of London, Camden, London, NW1
19 0TU, UK. Email: rpiercy@rvc.ac.uk

20

21 Funding information:

22 Horserace Betting Levy Board (HBLB) Grant & Anatomical Society Prize PhD Studentship

23

24

25

26

27

28

29

30

31

32

33

34 **Abstract**

35 The aetiology and pathophysiology of many diseases of the motor unit remain poorly
36 understood and the role of the neuromuscular junction (NMJ) in this group of disorders is
37 particularly overlooked, especially in humans, when these diseases are comparatively rare.
38 However, elucidating the development, function and degeneration of the NMJ is essential to
39 uncover its contribution to neuromuscular disorders, and to explore potential therapeutic
40 avenues to treat these devastating diseases. Until now, an understanding of the role of the
41 NMJ in disease pathogenesis has been hindered by inherent differences between rodent and
42 human NMJs: stark contrasts in body size and corresponding differences in associated axon
43 length underpin some of the translational issues in animal models of neuromuscular disease.
44 Comparative studies in large mammalian models, including examination of naturally-
45 occurring, highly prevalent animal diseases and evaluating their treatment, might provide
46 more relevant insight into the pathogenesis and therapy of equivalent human diseases. This
47 review argues that large animal models offer great potential to enhance our understanding of
48 the neuromuscular system in health and disease, and in particular when dealing with diseases
49 for which nerve length dependency might underly the pathogenesis.

50

51 Keywords: NMJ disorders, large animals, peripheral neuropathy, NMDs

52

53 **Introduction**

54 Within the neuromuscular system, the neuromuscular junction (NMJ) plays a fundamental
55 role: this highly specialised synapse transmits signals from motor neurons (MNs) to skeletal
56 muscles (Sanes & Lichtman, 1999) and is comprised of four basic cell types: the pre-synaptic
57 motor neuron and its axon (which terminates in the pre-synaptic nerve terminals); the post-
58 synaptic muscle fibre, which contains the post-synaptic motor endplate; terminal Schwann
59 cells capping the nerve terminal (Alhindi *et al.*, 2021) and kranocytes, which cap the NMJ
60 (Court *et al.*, 2008). For the majority of skeletal muscle fibres, each fibre has one NMJ
61 (Nishimune & Shigemoto, 2018) (Figure 1 - schematic healthy NMJ), but innervation
62 patterns differ between species and muscles: the sternomastoid muscle for example can have
63 up to seven endplate bands in the rabbit, compared to a single band in human and mouse
64 (Paul, 2001).

65 Recognition of the crucial role of the NMJ in the facilitation of movement sparked interest in
66 the study of the peripheral nervous system (PNS) as early as the 1700s (Lin & McArdle,
67 2021). Changes in pre- or post-synaptic NMJ size and/or configuration, and structural

68 changes of the motor neuron or post-synaptic muscle fibre, play a significant role in
69 neuromuscular disease pathogenesis. For example, fragmentation of the endplate (Slater,
70 2019), withdrawal of the motor nerve (denervation) (Wernig & Herrera, 1986; Chung *et al.*,
71 2017; Sleigh *et al.*, 2020), poly-innervation and axonal sprouting and loss of/clumping of
72 terminal neurofilaments are well-recognised features of NMJ remodelling (Wernig &
73 Herrera, 1986; Gordon *et al.*, 2004; Cifuentes-Diaz, 2002) (Figure 2 – schematic of diseased
74 NMJ). Subsequently, the identification of a structure-function relationship at the NMJ, such
75 as myelination of the motor axon for faster transmission, active zones juxtaposing
76 acetylcholine receptors for targeted release of synaptic vesicles containing neurotransmitter
77 and a “safety factor” guaranteeing generation of evoked end-plate potentials, suggested that
78 the study of NMJ morphology could teach us not only about the basic physiology of the
79 neuromuscular system, but also help develop treatments for motor dysfunction (Holz &
80 Fisher, 1999). The scientific community has used many animal models to study the impact of
81 pathological changes on the NMJ, but these consisted predominantly of small vertebrate
82 models such as rodents and *D. rerio* (zebrafish), and invertebrate models such as drosophila
83 (fruit fly) or *C. elegans* (roundworm). These are popular models due to their relatively
84 inexpensive husbandry costs, easy maintenance, and the multitude of well validated
85 experimental techniques that are available.

86 This review covers aspects of comparative NMJ research in traditional rodent models,
87 humans, and large mammals. It addresses translational issues in rodent models of NMJ, and
88 how genetic, morphological and physiological differences between humans and animals
89 might impact disease phenotypes and hence our understanding. It examines the opportunities
90 afforded by the study of large mammalian NMJs - from understanding how NMJ form
91 normally in a species of similar or larger size to humans, and how these NMJs respond to
92 injury in naturally-occurring large mammalian neuromuscular diseases (NMDs), particularly
93 in the context of length-dependent neuropathies.

94

95 **Cross-species accessibility and genetic heterogeneity of the mammalian NMJ**

96 Neuromuscular junctions are plastic, both in function and morphology—these adaptations are
97 muscle activity-driven (Deschenes *et al.*, 1993), mediated in part by skeletal muscle-derived
98 molecular factors such as peroxisome proliferator-activated receptor gamma coactivator 1-
99 alpha (PGC-1 α) (Arnold *et al.*, 2014). Study of the NMJ is rendered possible due to their
100 comparatively large size and their accessible (peripheral) location: this has led to their
101 extensive use as ‘model synapses’ in both vertebrates and invertebrates (Coers & Woolf,

102 1959; Slater, 2015) despite the significant differences that exist between neuromuscular and
103 inter-neuron synapses, such as those within the synaptic cleft and the post-synaptic
104 membrane (Zou & Pan, 2022); however, study of the NMJ has provided deeper insight into
105 the function of less accessible synapses within the CNS (Lin & McArdle, 2021).

106
107 Mammalian animal models are commonly used to study NMJ function and dysfunction.
108 Generally, the overall body plan (Bauplan) across mammals is encoded by highly conserved
109 structural genes that determine inter-species and intra-species variation (Travillion *et al.*,
110 2003). However, whilst the mammalian Bauplan is highly conserved, it is precisely those
111 inter-species differences that define the degree of conservation; in relation to the PNS, or the
112 NMJ in particular, this degree of cross-species conservation and its relevance to function are
113 less well explored. Therefore, differences between human and other mammals must be
114 considered carefully when translating research from animal models. Since rodent models are
115 used most commonly in biomedical research (Ellenbroek & Youn, 2016), there is a clear need
116 to establish the differences and similarities that their NMJs share with those of humans.

117
118 **Translational pitfalls in rodent NMJ form and physiology**
119 A translation gap exists in neurophysiological and neurodegenerative disease research, driven
120 in part by the failure of traditional laboratory models to recapitulate their human counterparts
121 in both phenotype and pathology (Eaton & Wishart, 2017). Economic necessity, due to costs
122 of studies in species other than traditional models, has resulted in the majority of structural
123 and functional features of the mammalian NMJ having been historically studied using rodents
124 (mice and rats). Beyond the obvious difference in body size between rodents and humans,
125 and the expected variations that exist between rodent strains (Harper, 2010; Hestehave *et al.*,
126 2020), there are also clear differences in NMJ form and function, over the lifetime of each
127 species, that should be considered in a translational setting. Firstly, some obvious
128 interspecies' NMJ morphological differences exist: human NMJs are significantly smaller
129 and more fragmented compared to their mouse counterparts, with much thinner pre-terminal
130 axons, more rudimentary nerve terminals and 'nummular' (coin-shaped) endplates (Jones *et al.*,
131 2017). Differences in neurotransmitter release represent a second distinction - the human
132 NMJ is the smallest (currently recognised) in nerve terminal surface area amongst vertebrates
133 (Slater, 2017; Gromova *et al.*, 2020; Jones *et al.*, 2017; Boehm *et al.*, 2020) and
134 consequently, only a small quantity of the neurotransmitter acetylcholine (ACh) is released
135 per action potential (quantal content). However, human NMJs have deeper post-synaptic

136 folding than mice, and the increased area containing sodium channels within the folds
137 contributes to the amplification of the ACh signal. As such, human NMJs have a lower
138 ‘safety factor’ (Wood & Slater, 2001) compared to those of mice that release more ACh
139 from larger nerve terminals. The safety factor is a ratio that describes the capacity of
140 neuromuscular transmission to elicit action potentials despite changes to neurotransmitter
141 release or physiological condition. Any value over 1 guarantees muscle contraction, a safety
142 factor below 1 would indicate failure of neuromuscular transmission. One review highlights
143 multiple studies from various research laboratories that have shown safety factors that vary
144 up to 4-fold between muscles of one species (Wood & Slater, 2001). Still, there is a lack of a
145 comprehensive comparative analysis across multiple species and muscles. Thirdly, when
146 considering different species as models of NMJ disorders, NMJ stability varies over time, as
147 does the occurrence of age-related NMJ degeneration. Several animal ageing studies describe
148 NMJs as inherently unstable, suggesting that motor endplates fragment as a consequence of
149 the ageing process, as cited by (Valdez *et al.*, 2010). Until recently, it was unclear whether
150 this was true in ageing humans (Oda, 1984) as the inherent complexity and ethical limitations
151 of human tissue sampling have hindered further progress in this area. Interestingly, despite
152 electrophysiological signs of NMJ transmission instability in ageing, such as an increase in
153 jitter and jiggle of motor unit potentials (Piasecki *et al.*, 2016; Hourigan *et al.*, 2015), recent
154 work shows that NMJ morphology in select leg muscles (extensor digitorum longus,
155 peroneus brevis, peroneus longus and soleus) is preserved as humans age (Jones *et al.*, 2017).
156 Likewise, the human NMJ appears stable in affected muscles following traumatic injury of
157 the brachial plexus and axillary nerve (Gupta *et al.*, 2020); similarly, the NMJs of rectus
158 abdominis appear stable in cancer cachexia (Boehm *et al.*, 2020), a condition wherein murine
159 models have suggested that denervation-related muscle wasting occurs (Daou *et al.*, 2020).
160 Therefore, given these morphological and physiological differences, bridging the resulting
161 translation gap requires more clinically relevant models of NMJ biological behaviour and
162 stability better to mimic the human phenotype, in health and disease, without masking it with,
163 for example, age-related degeneration.

164
165 The translation gap is also evident in the Charcot-Marie-Tooth (CMT) group of disorders
166 encompassing the most common forms of human hereditary motor and sensory neuropathy
167 (Pereira *et al.*, 2012); the need to find appropriate models of such human diseases is
168 especially pertinent. For example, murine models carrying heterozygous mutations in the
169 *Dynamin 2* gene, responsible for dominant-intermediate CMT type B, do not develop signs of

Commented [PRJ1]: Clearly cancer cachexia is not denervation - so is the point here that the changes are similar to those seen with denervation? Perhaps clarify.

170 an axonal or demyelinating neuropathy, characteristic of the human disease (Pereira *et al.*,
171 2020). Another study documented severe vocal fold paresis in humans, as a rare and
172 sometimes life-threatening clinical feature of CMT type 2, resulting from autosomal
173 dominant mutations of the canonical Notch ligand Jagged1 gene (or *JAG1*). A homozygous
174 *Jag1* mutation in mice is embryonically lethal while heterozygotes display only a mild
175 peripheral neuropathy: focally folded myelin was the only effect noted in recurrent laryngeal
176 nerve sections (Sullivan *et al.*, 2020). Finally, the Yars^{E196K} mouse model of dominant
177 intermediate CMT type C, fails to display a clear phenotype as heterozygotes; only as
178 homozygotes do animals display very mild disease-associated features (Hines *et al.*, 2021).

179

180 These examples highlight the translational difficulties with some rodent disease models:
181 clearly, researchers should be careful when extrapolating clinically relevant information, as
182 insights into the potential phenotypic, mechanistic and therapeutic avenues can be masked by
183 species differences. This, despite the historical successes of rodent models for tackling
184 distinct research questions, for example, in elucidating the role of PGC1alpha in NMJ
185 remodelling (Arnold *et al.*, 2014), there is a need to identify other suitable or better models
186 capable of more closely matching human morphology and pathophysiology.

187

188

189 **Comparative mammalian physiology and NMJ morphology**

190 As outlined in the previous section, for a model to be successful, it needs to mimic the human
191 condition; in the context of NMJ research at least, large mammalian models might offer a
192 solution to some phenotypic and physiological translational issues. The longer lifespan of
193 larger mammals (for example), in comparison to rodents, has great appeal for research, as this
194 could allow for more accurate modelling of chronic neurodegenerative disorders such as
195 Parkinson's Disease, Spinal muscular atrophy (SMA) and Amyotrophic lateral sclerosis
196 (ALS) (Duque *et al.*, 2015; Holm *et al.*, 2016; Eaton & Wishart, 2017; Yang *et al.*, 2021) at
197 pre-clinical levels or for following long term treatments. Age-dependent changes effect
198 readouts in ALS research for example. Mutations in superoxide dismutase 1 (*SOD1*) are
199 among those linked to familial forms of ALS. In a *SOD1* - G93A transgenic pig model,
200 movement disorders along with *SOD1* nuclear accumulation and ubiquitinated nuclear
201 aggregates appeared (Yang *et al.*, 2014), (something not observed in *SOD1*- G93A mouse
202 models) (Yang *et al.*, 2021). Thus, phenotypic differences between transgenic *SOD1* mice and

203 pigs suggest that large animal models might recapitulate better the age-dependent change
204 observed in human patients.

205

206 It is important to identify larger mammalian models with similar NMJ morphology and
207 physiological characteristics to humans since species differences in the functional properties
208 of neuromuscular transmission as previously outlined, for example, differences in quantal
209 content, ACh release, post-synaptic folding and nerve terminal area, could ultimately affect
210 pre-clinical translation. Similarity to human NMJ morphology might indicate similarity in the
211 synaptic transmission according to correlations drawn between quantal content/synaptic area,
212 and post-synaptic folding index (Wood & R. Slater, 2001). Thus, similarity in overall
213 anatomy might predict similarity in overall physiology. Therefore, future studies including
214 in-depth analysis of NMJ morphology via electron microscopy combined with
215 electrophysiological experiments, would allow measurement of post-synaptic folds and
216 morphometric correlation with variables of neuromuscular transmission such as quantal
217 content or endplate potentials. Additionally, with advances in spatial transcriptomics, it is
218 possible to link tissue morphology with its transcriptional landscape (Eng *et al.*, 2019; Xia *et*
219 *al.*, 2019; Marx, 2021) which might enable correlation between NMJ morphology and sub-
220 cellular transcription.

221

222 Both the advantages and disadvantages of rodent and large animal models need to be
223 considered when studying diseases involving the NMJ. As an example, the genetic pliability
224 of rodent models helps to recapitulate the human condition in the lab, yet, the homogeneity of
225 their genetic background can hinder experimental findings—for example, 10% of ALS
226 patients carry familial forms of the disease, yet representative lab animal models fail to
227 replicate the broad spectrum of human ALS phenotypes due to the much greater background
228 genetic heterogeneity within ALS patients (Picher-Martel *et al.*, 2016), thus affecting
229 translational efficacy of experimental data. In contrast, many large animal models occur
230 spontaneously on heterogeneous (outbred) backgrounds, reflecting the human situation (Casal
231 & Haskins, 2006).

232

233 Whilst genetic conservation is one important factor (Barthélémy *et al.*, 2019), the
234 resemblance of anatomy and physiology between animal models and humans should also be
235 scrutinised. The similarity of brain size, nerve length, muscle size, NMJ morphology and
236 functional properties of muscles are essential factors to consider when assessing the

237 advantages and disadvantages of animal models. One particular advantage of large animal
238 models is the similarity in NMJ morphology to those of humans (Boehm *et al.*, 2020).
239 Exploring this similarity could prove to be of substantial translational benefit, in particular
240 given other anatomical similarities of the CNS; for example pig and sheep are more similar to
241 the human brain mass and skull thickness than rodents or even non-human primates
242 (Pelekanos *et al.*, 2018).

243
244 A recent study comparing selected pelvic limb muscle NMJ morphologies in mouse, cat, dog,
245 sheep, pig, and human, revealed baseline data of the mammalian NMJ, laying the
246 groundwork for subsequent comparative studies of larger mammalian NMJs (Boehm *et al.*,
247 2020). Whilst the study identified that sheep had the closest morphology to the human NMJ,
248 it also concluded that there are stark differences in overall NMJ morphology between human
249 and smaller mammalian models, i.e. mouse, cat and dog. In contrast, the larger mammalian
250 models (sheep and pig) with comparable body weight to humans, were more similar (Boehm
251 *et al.*, 2020). For this reason, we herein focus on larger mammalian models—here defined as
252 animals of a similar or larger size than humans—and the benefits that the study of their
253 neuromuscular system could have in translational research.

254
255 Figure 3 illustrates the similarities in size and overall NMJ morphology between sheep, pig,
256 pony and human, and the stark contrast between NMJs in these larger mammalian models
257 compared with those of mice. Whilst the mouse has a much larger NMJ and wider diameter
258 innervating motor axon, the sheep, pig and human NMJ are comparatively similar in NMJ
259 size and axon diameter (Boehm *et al.*, 2020). Pony NMJs (Cahalan *et al.*, 2022, under review)
260 are strikingly similar to the human NMJ in appearance, although their terminal motor axon
261 diameter is larger than that of humans. The suitability then of larger mammalian models as
262 possible substitutes or additions to rodent models of these neurodegenerative diseases will
263 require further study.

264

265

266 **Uncovering comparative evolutionary relationships at the NMJ**

267 Aside from linking the relationship between NMJ morphology and physiology, a better
268 understanding of the genetic mechanisms underpinning these might help address gaps in
269 translational understanding. For example, it is unknown whether differences in NMJ
270 morphology between species are linked to phylogenetic distance, or selective pressure and we

271 know little about conserved mechanisms within the neuromuscular system of larger
272 mammals. For example, mechanisms contributing to sarcopenia-related muscle wasting and
273 neurogenic muscle atrophy are primarily being investigated using rodent models - for review
274 see (Tintignac *et al.*, 2015). Whilst a recent study highlighted species-specific differences—
275 and similarities—in molecular pathways during muscle ageing between mouse, rat and
276 human (Börsch *et al.*, 2021).

277
278 Since humans and mouse are descended from a younger common ancestor (the superorder
279 Euarchontoglires) than the sheep, pig and pony (the superorder Laurasiatheria), which
280 diverged later, one might assume that murine models are more similar to the human (Figure
281 4A). However, phylogenetic divergence does not necessarily inform us about similarity of
282 genetic sequence or morphology. For example, out of 22 select genes associated with
283 neuromuscular disorders, the pig has the highest percentage of nucleotide sequence identity
284 to the human as compared with dog, mouse and rat (Barthélémy *et al.*, 2019). Since there are
285 species-specific differences in pre- and post-synaptic morphology between species (Figure 3),
286 one might wonder whether motor nerve (pre-synapse) or target skeletal muscle fibre (post-
287 synapse) underwent different functional adaptations, or whether purely genetic drift was
288 responsible for species-specific differences. In the case of genetic drift, one would expect
289 both pre- and post-synaptic NMJ morphology of species from Figure 3 to cluster as they do
290 in their phylogenetic tree (Figure 4A). Whilst mouse NMJ morphology is strikingly different
291 from those of sheep, pig, human and pony, at both pre- and post-synapse, neither pre- nor
292 post-synaptic NMJ morphology across species matches their phylogenetic divergence (Figure
293 4B). Despite small differences in their clustering between pre- and post-synaptic NMJ
294 morphology, those of sheep and pig, (at least in select pelvic limb muscles), are remarkably
295 similar to those of humans, as exemplified by recent comparative work (Boehm *et al.*, 2020).
296 A study of NMJ morphology between *Drosophila* species showed a similar result: whilst
297 differences in NMJ morphology were found between *Drosophila* species, these were not
298 aligned with phylogenetic distance between these species - differences in *Drosophila* NMJ
299 structure and function result from selection pressure and adaptation to environmental factors
300 rather than purely genetic drift (Campbell & Ganetzky, 2012). Data from dogs suggests a
301 similar conclusion and indicates that larger mammals might be genetically more similar to
302 humans than rodents (Wang *et al.*, 2013; Barthélémy *et al.*, 2019); selection pressure due to
303 environmental factors and functional adaptations might shape both genetic factors and
304 associated NMJ morphology.

305 Advances in molecular biology and sequencing technologies will hopefully allow us to shed
306 light on conserved pathways associated with NMJ morphology and function between larger
307 mammalian models and humans and might uncover the mechanisms of parallel evolution that
308 can ultimately aid in our translational efforts and drug discovery in certain neuromuscular
309 diseases.

310
311
312

313 **An unexplored area of NMJ research: large mammalian NMDs**

314 Comparatively little is known about healthy large mammalian NMJ morphology in general,
315 and this is condensed within a few recent papers - this knowledge deficit is more conspicuous
316 in the field of large animal neuromuscular diseases, where there is little to no published NMJ
317 data.

318 As previous sections have outlined, significant differences exist between human and rodent
319 models. For example, compared to rodents, it seems reasonable that large animal models,
320 with similar axon lengths to humans, will reveal more about neuropathies with a length-
321 dependency.

322 Axonopathies, characterised by axonal degeneration and ultimately fragmentation, are the
323 most common form of PNS disease in all species (Lanigan *et al.*, 2021). The nerve fibres are
324 affected in a length-dependent pattern in distal dying-back axonopathies. In humans, height is
325 correlated with an increased risk of various peripheral neuropathies, including in HIV and
326 type 2 diabetes patients (Cheng *et al.*, 2006; Cherry *et al.*, 2009). Thus, taller subjects are
327 more likely to develop lower extremity peripheral neuropathy, with a cut off at >1.70 m of
328 height (Cherry *et al.*, 2009). This is likely because the longer the nerve, the more vulnerable
329 the axon is to insult, and to disturbances in axonal transport, likely because of its exaggerated
330 metabolic demands. Therefore, the first advantage of using large mammals is a better
331 recapitulation of the length of affected nerves. For example, pigs and sheep have recently
332 successfully been used as preclinical models to study nerve regeneration following peripheral
333 nerve injury (D. Alvites *et al.*, 2021; Burrell *et al.*, 2020), suggesting potential for future
334 translational clinical applications to humans and other veterinary species.

335 Given the deficiency of knowledge regarding large mammal NMJ morphology in disease
336 states, it seems reasonable that its study will have translational impact, allowing a better
337 understanding of changes at the human NMJ. As such, what follows is a summary of

338 pertinent large animal NMDs. For each, there is an opportunity for NMD translational
339 discovery.

340

341 **Horses**

342 ***Equine recurrent laryngeal neuropathy (RLN)***

343 Equine recurrent laryngeal neuropathy (RLN) is a common neuromuscular condition
344 primarily affecting tall horse breeds such as Thoroughbreds and various Draughts (Draper &
345 Piercy, 2018); as a neurodegenerative disorder affecting the recurrent laryngeal nerves (RLn)
346 - the longest equine motor axons, measuring up to 2.5 m - it is likely one of the more
347 prevalent, length-dependent neuropathies in large mammals. It is characterised by varying
348 degrees of arytenoid cartilage paresis, primarily on the left side, likely because the left-sided
349 nerve is longer than that on the right side. Indeed, evidence suggests that most, if not all,
350 large breed horses have varying severities of this disorder (Draper & Piercy, 2018). Affected
351 horses produce abnormal respiratory sounds during exercise and show exercise intolerance in
352 the most severe cases caused by the associated paresis of the denervated cricoarytenoideus
353 dorsalis muscles that normally abduct the vocal cords, opening the rima glottidis. Despite the
354 high prevalence, the exact cause of RLN remains unclear, though it likely includes acquired
355 and genetic factors (Draper & Piercy, 2018). Length-dependency is also a common feature of
356 human peripheral neuropathies that have a genetic basis, such as in CMT 1A (Scherer &
357 Wrabetz, 2008; Krajewski *et al.*, 2000), or in certain acquired diabetic neuropathies (Kazamel
358 & Dyck, 2015). Typically, CMT involves the distal extremities, although a few patient
359 subtypes (mainly CMT4A, CMT2A and CMT2C - select familial examples are mentioned in
360 the section '**Translational pitfalls in rodent NMJ form and physiology**') also develop
361 laryngeal paralysis (Zambon *et al.*, 2017). Note that in some patient subsets, CMT first
362 presents with atrophy and weakness of the intrinsic muscles of the hands, without
363 involvement of lower limbs until later in the disease course, indicating the clinical
364 heterogeneity of CMT disorders (Macken *et al.*, 2020) and the presence of disease factors
365 beyond pure length-dependency. Some of the neuropathological features associated with
366 CMT diseases (particularly CMT2A, E and F), such as loss of myelinated nerve fibres and
367 organelle-containing paranodal evaginations (Millecamps & Julien, 2013), also occur in RLN
368 (Duncan, 1978) – the study of the equine NMJ in these cases might then yield translatable
369 insights into chronic NMJ (mal)adaptions in these disorders. Recently, novel treatments for
370 RLN have shown promising results. For example, a cervical nerve transplantation technique

371 enabled reinnervation of the cricoarytenoideus dorsalis muscle (Rossignol *et al.*, 2018) in
372 affected horses.

373

374 ***Equine motor neuron disease (EMND)***

375 Equine motor neuron disease is a neurodegenerative neuropathy characterised by
376 generalised paresis, muscle fasciculations, muscle atrophy, and progressive weight loss (Sisó
377 *et al.*, 2006; Sasaki *et al.*, 2016; Banfield *et al.*, 2019). Pathology studies show motor neuron
378 degeneration in the spinal cord and brain stem, leading to axonal degeneration in the CNS
379 and PNS. The aetiology appears to be related primarily to an acquired deficiency of anti-
380 oxidants, especially of vitamin E (Mohammed *et al.*, 2007).

381

382 ***Acquired equine polyneuropathy (AEP)***

383 Acquired equine polyneuropathy is a sometimes-fatal neurological disease characterised by
384 pelvic limb paresis. It has been mainly described in Sweden, Norway, and Finland and is also
385 referred to as “Scandinavian knuckling syndrome” (Gröndahl *et al.*, 2012; Hanche-Olsen *et*
386 *al.*, 2017a). Despite the geographical pattern and association with forage feeding, the
387 aetiopathogenesis is unclear. Affected horses present with a polyneuropathy with
388 inflammatory demyelination and Schwann cell inclusions, suggestive of a primary
389 Schwannopathy (Hanche-Olsen *et al.*, 2017a,b). These horses, regardless of size, develop
390 recurrent laryngeal nerve lesions yet do not demonstrate clinically defective laryngeal
391 function.

392

393 **Goats**

394 Laryngeal neuropathy has been described in goats with clinical signs of copper deficiency
395 (Sousa *et al.*, 2016). The main lesions were axonal degeneration of the RLNs and atrophy of
396 intrinsic laryngeal muscles. Another acquired peripheral neuropathy in the goat is caused by
397 coyotillo (*Karwinskia humboldtiana*, also known as Humboldt’s Buckthorn) poisoning
398 (Charlton *et al.*, 1971), where the results suggested a primary mitochondrial injury in
399 Schwann cells with resulting impaired axonal transport, myelin splitting and segmental
400 demyelination in long nerves such as the sciatic. A subclinical demyelinating polyneuropathy
401 was recently studied in goats (Skedsmo *et al.*, 2020). This disease was caused by the loss of
402 the cellular prion protein (PrPC), confirming the importance of PrPC for peripheral nerve
403 myelin maintenance.

404

405 **Sheep**

406 The most common neurodegenerative disorder described in sheep is neuroaxonal dystrophy,
407 characterized by numerous axonal swellings, myelin loss, and axonal degeneration,
408 particularly in the spinal cord and sciatic nerve (Finnie & Manavis, 2017). It has been
409 observed in juvenile and newborn Australian Merino lambs and Suffolk sheep (Harper *et al.*,
410 1986; Bourke, 1995; Sisó *et al.*, 2006).

411
412 As previously mentioned, the ovine NMJ most closely resembles the human NMJ (Figure 3)
413 (Boehm *et al.*, 2020). Sheep have been used as models of periphery nerve injury affecting the
414 cervical nerve roots (Hems & Glasby, 1992), C6 ventral root avulsion (Fullarton *et al.*, 2001)
415 and the facial nerve (Starritt *et al.*, 2011). Sheep models have been used to recapitulate Batten
416 disease (Weber & Pearce, 2013), and the first gene-edited ovine model of neuronal ceroid
417 lipofuscinoses has recently been generated (Eaton *et al.*, 2019).

418 Additionally, aged sheep are used as a model for functional electrical stimulation of the
419 recurrent laryngeal nerve, advancing the understanding and the clinical translation of
420 conditions with atrophied laryngeal muscles such as vocal fold paralysis (Karbiener *et al.*,
421 2016; Gugatschka *et al.*, 2018).

422

423

424 **Pigs**

425 Similar to the ovine NMJ, the porcine NMJ closely resembles those of humans (Figure 3),
426 improving its translational potential for the study of motor neuron diseases (Boehm *et al.*,
427 2020). A spontaneous porcine motor neuron disease (SPMND), with features similar to the
428 equine disease, has been described in feeder pigs (Wohlsein *et al.*, 2012). A putative
429 peripheral neuropathy with unclear aetiology has been described in suckling piglets (Sályi *et al.*,
430 2000). This was characterised by degeneration, demyelination, and necrosis of the tibial
431 nerve and the common fibular nerve, with no CNS involvement.

432 Pigs are used to model Spinal Muscular Atrophy (SMA), a human genetic disorder
433 characterised by motor neuron degeneration and paresis (Duque *et al.*, 2015). Results from
434 porcine models and other large animals of SMA have not only shed light on the molecular
435 mechanisms of the disease, they have also provided valuable insights into biomarkers and
436 gene delivery strategies, therefore allowing a quicker advancement of gene therapy and
437 similar molecular approaches to the clinic (Bevan *et al.*, 2011; Iyer *et al.*, 2017).

438

439

440 **Cattle**

441 CMT type 4H in humans arises through homozygous mutations in the *FGD4* gene. A recent
442 study of Holstein Friesian cattle with a homozygous splice site mutation in this gene revealed
443 clinical signs of stumbling and loss of coordination in animals close to 2 years of age (early
444 adulthood). Gross post-mortem abnormalities were not observed. Examination of a range of
445 peripheral nerves revealed demyelination and remyelination, with Schwann cell hyperplasia
446 and hypertrophy, onion bulb formation and decreased myelinated fiber density. These
447 changes can also be found in human CMT type 4H and in *FGD4* KO mouse models (Dittmer
448 et al., 2022).

449

450 Bovine spastic paresis (BSP) is a relatively common progressive NMD affecting many breeds
451 of cattle and is characterised by spastic contractions of one or more pelvic limb muscles. The
452 *gastrocnemius* muscle is the most commonly affected, with spastic paresis causing the animal
453 to repetitively stretch the affected limb in a caudal direction. BSP likely has a genetic basis,
454 however, an exact aetiopathogenesis is unknown – histopathology of the spinal cord, tibial
455 nerves and muscle tissue of affected animals do not reveal abnormalities. A functional
456 pathology occurring from overstimulation and/or lack of inhibition from centrally controlled
457 spinal cord γ motor neurones is presumed to occur. (De Vlaminck *et al.*, 2014).

458

459 **Llamas and alpacas**

460 Paralysis of the diaphragm with phrenic nerve degeneration has been reported in llamas and
461 alpacas (Bedenice *et al.*, 2002; Byers *et al.*, 2011; Uzal *et al.*, 2012). Neuropathological
462 studies showed that affected axons varied from being intact to being vacuolated and
463 degenerated with loss of neurofilaments. The aetiology of this phrenic nerve neuropathy
464 could not be elucidated.

465

466 **The promise and practice of stem cell work**

467 Stem cell technologies have emerged over the last two decades to create a field with much
468 promise for generating therapeutics and cellular regenerative biology insights for chronic
469 degenerative disorders (Zakrzewski *et al.*, 2019). Insights into the physiological and
470 pathological function of the NMJ might come from iPSC-derived models (Thompson *et al.*,
471 2012; Lin *et al.*, 2019), or cultured neurons, which have now been generated from large
472 mammals (Pessôa *et al.*, 2019; Bressan *et al.*, 2020), including horses (Adalbert *et al.*, 2022).

473 iPSCs can be differentiated into muscle or neural tissue, with a future promise of in vitro
474 NMJ models (Jongh *et al.*, 2021), providing an understanding of the cellular and molecular
475 mechanism and the aetiology underlying many NMJ-related disorders and peripheral
476 neuropathies. Besides offering a possible disease modelling platform, iPSC- and other cell-
477 based models can also act as an ex vivo platform to test potential therapeutic strategies and
478 drugs.

479
480 Large animal models are essential for the translation of therapeutics that utilise stem cell and
481 tissue engineering strategies (Ribitsch *et al.*, 2020). In addition, trials to treat large animals
482 (e.g., dogs and horses) with stem cell- and biomaterial-based therapies are also underway. For
483 example, stem cell therapy using adult mesenchymal stem cells derived from bone marrow is
484 approved in equine medicine for musculoskeletal disorders (Ortved, 2018). Veterinary
485 regenerative medicine is growing in popularity (Koch *et al.*, 2009; Smith *et al.*, 2014;
486 Barrachina *et al.*, 2018). In the future, these novel approaches could be applied to peripheral
487 nerve regeneration in humans, providing a treatment for peripheral neuropathies.

488
489
490 **Weighing the translational benefits and costs of studying NMJs in large animal models**

491 The complexity of human diseases necessarily means that no one animal model will likely
492 replicate all aspects of the disease. However, to facilitate the most efficient translation from
493 bench to bedside, the research community should aim to recapitulate the condition wherever
494 possible (Eaton & Wishart, 2017). Murine models are currently the most popular model for
495 the study of human disease—in particular due to their quick reproductive rate, low
496 maintenance cost, ease of genetic manipulation and variety of experimental tools developed
497 to study them (Chung *et al.*, 1997)—The emergence of nuclease-mediated genome editing
498 technology (CRISPR/Cas9) however, recently used to create a knock-in pig model with
499 features of Huntingdon's disease (Yan *et al.*, 2018), has greatly improved the efficiency of
500 generating transgenic animals - see review of genetically modified neurogenerative large
501 animal models (Yang *et al.*, 2021). Thus, the appeal of large animal models across a range of
502 clinical applications should be considered.

503 Despite the comparatively higher cost and level of maintenance and workforce involved with
504 large animals, the benefits that the similarity of these models could bring, should be
505 considered as an encouragement for the research community. A higher cost is somewhat
506 offset by the very high prevalence of certain large animal diseases—for example, RLN has a

507 cited worldwide clinically-relevant occurrence of between 2-11% in Thoroughbred horses
508 (Boyko *et al.*, 2014), whereas most human neuropathies are comparatively rare. A high
509 natural prevalence of certain large animal diseases might negate the need to maintain colonies
510 of affected animals, with associated welfare and ethical advantages.

511 Neurodegenerative conditions that occur naturally in large animals and humans, such as the
512 neuropathies outlined above, should be of particular benefit for clinical translation (Eaton &
513 Wishart, 2017), as one could expect more commonalities in disease onset and progression.
514 More translatable data ultimately contributes to a reduced failure rate of therapeutics within
515 the drug discovery pipeline, as currently, which still occurs commonly in human clinical
516 trials (Seyhan, 2019). Given that drugs typically take over 12 years to get from the lab
517 through to approval and development costs can exceed \$1 billion (Mohs & Greig, 2017), it is
518 in everyone's interest to accelerate this process and reduce the attrition rate of therapeutics
519 and also reduce associated costs. Animal models that better mimic human NMJ morphology,
520 and length dependency of axon functions, will hopefully allow researchers to identify drugs
521 that are less likely to fail in clinical trials, whilst reducing costs.

522

523 **Conclusions**

524 The species and disease model of choice are undoubtedly relevant to answering both research
525 questions and clinical problems. The aetiology of peripheral neuropathies in large animals is
526 often undetermined, and the NMJ involvement is overlooked. Large animal models have
527 great potential to enhance our understanding of the neuromuscular system in health and
528 disease. Although elevated costs can constrain large animal studies, their high prevalence and
529 application of a more appropriate comparative approach should help close the translational
530 gap between preclinical and clinical responses.

531

532 **Acknowledgements**

533 The authors declare no conflict of interest.

534

535

536

537

538

539

540 References

541

542 Adalbert R, Cahalan S, Eleanor L. Hopkins, et al. (2022) Cultured dissociated primary dorsal
543 root ganglion neurons from adult horses enable study of axonal transport. *Journal of*
544 *Anatomy*. <https://doi.org/10.1111/joa.13719>

545

546 Alhindi A, Boehm I, Forsythe RO, et al. (2021) Terminal Schwann cells at the human
547 neuromuscular junction. *Brain Communications*, fcab081. doi:10.1093/braincomms/fcab081.
548 Arnold A-S, Gill J, Christe M, et al. (2014) Morphological and functional remodelling of the
549 neuromuscular junction by skeletal muscle PGC-1 α . *Nature communications* 5, 3569.
550 doi:10.1038/ncomms4569.

551

552 Awano T, Johnson GS, Wade CM, et al. (2009) Genome-wide association analysis reveals a
553 SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral
554 sclerosis. *PNAS* 106, 2794–2799. doi:10.1073/pnas.0812297106.

555

556 Banfield J, Lisak R, Omar A, et al. (2019) Investigating the Risk of Equine Motor Neuron
557 Disease in a Brazilian Stable and Successful Intervention. *Journal of equine veterinary*
558 *science* 77, 132–138. doi:10.1016/j.jevs.2019.02.024.

559

560 Barrachina L, Romero A, Zaragoza P, et al. (2018) Practical considerations for clinical use of
561 mesenchymal stem cells: From the laboratory to the horse. *The Veterinary Journal* 238, 49–
562 57. doi:10.1016/j.tvjl.2018.07.004.

563

564 Barthélémy I, Hitte C, Tiret L (2019) The dog model in the spotlight: Legacy of a trustful
565 cooperation, doi:10.3233/JND-190394.

566

567 Bedenice D, Mazan MR, Kuehn H, et al. (2002) Diaphragmatic Paralysis Due to Phrenic
568 Nerve Degeneration in a Llama. *Journal of Veterinary Internal Medicine* 16, 603–606.
569 doi:10.1111/j.1939-1676.2002.tb02395.x.

570 Bevan AK, Duque S, Foust KD, et al. (2011) Systemic gene delivery in large species for
571 targeting spinal cord, brain, and peripheral tissues for pediatric disorders. *Molecular Therapy*
572 19, 1971–1980. doi:10.1038/mt.2011.157.

573

574 Boehm I, Alhindi A, Leite AS, et al. (2020) Comparative anatomy of the mammalian
575 neuromuscular junction. *J Anat*, joa.13260. doi:10.1111/joa.13260.

576

577 Boehm I, Miller J, Wishart TM, et al. (2020) Neuromuscular junctions are stable in patients
578 with cancer cachexia. *Journal of Clinical Investigation* 130, 1461–1465.
579 doi:10.1172/JCI128411.

580

581 Börsch A, Ham DJ, Mittal N, et al. (2021) Molecular and phenotypic analysis of rodent
582 models reveals conserved and species-specific modulators of human sarcopenia.
583 *Communications Biology* 4, 194. doi:10.1038/s42003-021-01723-z.

584

585 Bourke C (1995) The clinical differentiation of nervous and muscular locomotor disorders of
586 sheep in Australia. *Australian Vet J* 72, 228–234. doi:10.1111/j.1751-0813.1995.tb03528.x.

587

588 Boyko AR, Brooks S a, Behan-Braman A, et al. (2014) Genomic analysis establishes
589 correlation between growth and laryngeal neuropathy in Thoroughbreds. *BMC genomics* 15,
590 259. doi:10.1186/1471-2164-15-259.

591

592 Bressan FF, Bassaneze V, de Figueiredo Pessôa LV, et al. (2020) Generation of induced
593 pluripotent stem cells from large domestic animals. *Stem Cell Res Ther* 11, 247–247.
594 doi:10.1186/s13287-020-01716-5.

595

596 Bruun CS, Jäderlund KH, Berendt M, et al. (2013) A Gly98Val Mutation in the N-Myc
597 Downstream Regulated Gene 1 (NDRG1) in Alaskan Malamutes with Polyneuropathy F.
598 Palau, ed. *PLoS ONE* 8, e54547. doi:10.1371/journal.pone.0054547.

599

600 Burrell JC, Browne KD, Dutton JL, et al. (2020) A Porcine Model of Peripheral Nerve Injury
601 Enabling Ultra-Long Regenerative Distances: Surgical Approach, Recovery Kinetics, and
602 Clinical Relevance. *neuros*, 833–846. doi:doi: 10.1093/neuros/nyaa106.

603 Byers S, Barrington G, Nelson D, et al. (2011) Neurological causes of diaphragmatic
604 paralysis in 11 alpacas (*Vicugna pacos*). *J Vet Intern Med* 25, 380–385. doi:10.1111/j.1939-
605 1676.2010.0661.x.
606

607 Cahalan, S. D., Boehm, I., Perkins JD, et al. (2022) ‘A method to identify, dissect and stain
608 equine neuromuscular junctions for morphological analysis’ Publication under review
609

610 Campbell M, Ganetzky B (2012) Extensive morphological divergence and rapid evolution of
611 the larval neuromuscular junction in *Drosophila*. *Proceedings of the National Academy of*
612 *Sciences* 109, E648–E655. doi:10.1073/pnas.1201176109.
613

614 Casal M, Haskins M (2006) Large animal models and gene therapy. *Eur J Hum Genet* 14,
615 266–272. doi:10.1038/sj.ejhg.5201535.
616

617 Charlton KM, Claborn LD, Pierce KR (1971) A neuropathy in goats caused by experimental
618 coyotillo (*Karwinskia humboldtiana*) poisoning: clinical and neurophysiologic studies.
619 *American journal of veterinary research* 32, 1381–9.
620

621 Cheng YJ, Gregg EW, Kahn HS, et al. (2006) Peripheral Insensate Neuropathy—A Tall
622 Problem for US Adults? *American Journal of Epidemiology* 164, 873–880.
623 doi:10.1093/aje/kwj281.
624

625 Cherry CL, Affandi JS, Imran D, et al. (2009) Age and height predict neuropathy risk in
626 patients with HIV prescribed stavudine. *Neurology* 73, 315–320.
627 doi:10.1212/WNL.0b013e3181af7a22.
628

629 Chung SK, Lee AY, Chung SS (1997) Mouse models for human diseases. *Hong Kong*
630 *medical journal = Xianggang yi xue za zhi* 3, 201–209. doi:10.1002/0471140856.tx0213s31.
631

632 Chung T, Park JS, Kim S, et al. (2017) Evidence for dying-back axonal degeneration in age-
633 associated skeletal muscle decline. *Muscle & Nerve* 55, 894–901. doi:10.1002/mus.25267.
634

635 Cifuentes-Diaz C (2002) Neurofilament accumulation at the motor endplate and lack of
636 axonal sprouting in a spinal muscular atrophy mouse model. *Human Molecular Genetics* 11,
637 1439–1447. doi:10.1093/hmg/11.12.1439.

638

639 Coers C, Woolf AL (1959) *The Innervation of Muscle: A Biopsy Study*, Springfield, Ill.,
640 doi:10.1093/bja/32.3.148.

641

642 Court FA, Gillingwater TH, Melrose S, et al. (2008) Identity, developmental restriction and
643 reactivity of extralaminar cells capping mammalian neuromuscular junctions. *Journal of Cell*
644 *Science* 121, 3901–3911. doi:10.1242/jcs.031047.

645

646 D. Alvites R, V. Branquinho M, Sousa AC, et al. (2021) Establishment of a Sheep Model for
647 Hind Limb Peripheral Nerve Injury: Common Peroneal Nerve. *IJMS* 22, 1401.
648 doi:10.3390/ijms22031401.

649

650 Daou N, Hassani M, Matos E, et al. (2020) Displaced Myonuclei in Cancer Cachexia Suggest
651 Altered Innervation. *International Journal of Molecular Sciences* 21, 1092.
652 doi:10.3390/ijms21031092.

653

654 Deschenes MR, Maresh CM, Crivello JF, et al. (1993) The effects of exercise training of
655 different intensities on neuromuscular junction morphology. *Journal of Neurocytology* 22,
656 603–615. doi:10.1007/BF01181487.

657

658 De Vlamynck C, Pille F, Vlamynck L (2014) Bovine spastic paresis: Current Knowledge and
659 scientific voids. *The Veterinary Journal* 2, 229-235. <https://doi.org/10.1016/j.tvjl.2014.07.015>

660

661 Dittmer KE, Neeley C, et al. Pathology of the peripheral neuropathy Charcot-Marie-Tooth
662 disease type 4H in Holstein Friesian cattle with a splice site mutation in FGD4. *Veterinary*
663 *Pathology* 3, 442-450. doi:10.1177/03009858221083041.

664

665 Draper ACE, Piercy RJ (2018) Pathological classification of equine recurrent laryngeal
666 neuropathy. *J Vet Intern Med* 32, 1397–1409. doi:10.1111/jvim.15142.

667 Draper ACE, Wilson Z, Maile C, et al. (2020) Species-specific consequences of an E40K
668 missense mutation in superoxide dismutase 1 (SOD1). *FASEB j* 34, 458–473.
669 doi:10.1096/fj.201901455R.
670

671 Drögemüller C, Becker D, Kessler B, et al. (2010) A Deletion in the N-Myc Downstream
672 Regulated Gene 1 (NDRG1) Gene in Greyhounds with Polyneuropathy A. Lewin, ed. *PLoS*
673 *ONE* 5, e11258. doi:10.1371/journal.pone.0011258.
674

675 Duncan ID (1978) A light and electron microscopic study of the neuropathy of Equine
676 Idiopathic laryngeal hemiplegia. 483–501.
677

678 Duque SI, Arnold WD, Odermatt P, et al. (2015) A large animal model of spinal muscular
679 atrophy and correction of phenotype: SMA in Pig. *Ann Neurol* 77, 399–414.
680 doi:10.1002/ana.24332.
681

682 Eaton SL, Proudfoot C, Lillico SG, et al. (2019) CRISPR/Cas9 mediated generation of an
683 ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease). *Sci Rep* 9, 9891.
684 doi:10.1038/s41598-019-45859-9.
685

686 Eaton SL, Wishart TM (2017) Bridging the gap: large animal models in neurodegenerative
687 research. *Mammalian Genome* 28, 324–337. doi:10.1007/s00335-017-9687-6.
688

689 Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a rat race?
690 *Disease Models & Mechanisms* 9, 1079–1087. doi:10.1242/dmm.026120.
691

692 Eng C-HL, Lawson M, Zhu Q, et al. (2019) Transcriptome-scale super-resolved imaging in
693 tissues by RNA seqFISH+. *Nature* 568, 235–239. doi:10.1038/s41586-019-1049-y.
694

695 Finnie JW, Manavis J (2017) Axonal spheroids in ovine neuroaxonal dystrophy are
696 immunopositive to kinesin and dynein. *Journal of Veterinary Diagnostic Investigation* 29,
697 852–855. doi:10.1177/1040638717721579.
698

699 Fullarton AC, Myles LM, Lenihan DV, et al, (2001) *British Journal of Plastic Surgery* 8, 697-
700 704. <https://doi.org/10.1054/bjps.2001.3700>

701
702 Furuoka H, Amanai H, Taniyama H, et al. (1992) Peripheral neuropathy in German Shepherd
703 Dogs. *Journal of Comparative Pathology* 107, 169–177. doi:10.1016/0021-9975(92)90033-Q.
704
705 Galili T (2015) dendextend: an R package for visualizing, adjusting and comparing trees of
706 hierarchical clustering. *Bioinformatics* 31, 3718–3720. doi:10.1093/bioinformatics/btv428.
707
708 Geiger DA, Miller AD, Cutter-Schatzberg K, et al. (2009) Encephalomyelopathy and
709 Polyneuropathy Associated with Neuronal Vacuolation in Two Boxer Littermates. *Veterinary*
710 *Pathology* 46, 1160–1165. doi:10.1354/vp.09-VP-0010-S-FL.
711
712 Gordon T, Hegedus J, Tam SL (2004) Adaptive and maladaptive motor axonal sprouting in
713 aging and motoneuron disease. *Neurological Research* 26, 174–185.
714 doi:10.1179/016164104225013806.
715
716 Granger N (2011) Canine inherited motor and sensory neuropathies: An updated
717 classification in 22 breeds and comparison to Charcot–Marie–Tooth disease. *The Veterinary*
718 *Journal* 188, 274–285. doi:10.1016/j.tvjl.2010.06.003.
719
720 Gromova A, Albert R La Spada (2020) Harmony Lost: Cell-Cell Communication at the
721 Neuromuscular Junction in Motor Neuron Disease. *Trends in Neurosciences*, 43,9 709-724.
722 doi:10.1016/j.tins.2020.07.002
723
724 Gröndahl G, Hanche-Olsen S, Brøjer J, et al. (2012) Acquired equine polyneuropathy in
725 Norway and Sweden: A clinical and epidemiological study. *Equine Veterinary Journal* 44,
726 36–44. doi:10.1111/j.2042-3306.2012.00679.x.
727
728 Gugatschka M, Jarvis JC, Perkins JD, et al. (2018) Functional Electrical Stimulation Leads to
729 Increased Volume of the Aged Thyroarytenoid Muscle: Electrical Stimulation of Laryngeal
730 Muscles. *The Laryngoscope* 128, 2852–2857. doi:10.1002/lary.27342.
731
732 Gupta R, Chan JP, Uong J, et al. (2020) Human motor endplate remodeling after traumatic
733 nerve injury. *Journal of Neurosurgery* 1, 1–8. doi:10.3171/2020.8.JNS201461.

734 Hanche-Olsen S, Kielland C, Ihler CF, et al. (2017a) Long-term follow-up of Norwegian
735 horses affected with acquired equine polyneuropathy. *Equine Veterinary Journal* 49, 577–
736 583. doi:10.1111/evj.12674.
737

738 Hanche-Olsen S, Matiasek K, Molín J, et al. (2017b) Acquired equine polyneuropathy of
739 Nordic horses: A conspicuous inclusion body schwannopathy. *Neuromuscular Disorders* 27,
740 931–941. doi:10.1016/j.nmd.2017.06.005.
741

742 Harper A (2010) Mouse models of neurological disorders—A comparison of heritable and
743 acquired traits. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1802,
744 785–795. doi:10.1016/j.bbadis.2010.05.009.
745

746 Harper PAW, Duncan DW, Plant JW, et al. (1986) Cerebellar abiotrophy and segmental
747 axonopathy: two syndromes of progressive ataxia of Merino sheep. *Australian Vet J* 63, 18–
748 21. doi:10.1111/j.1751-0813.1986.tb02865.x.
749

750 Hems TE, Glasby MA (1992) Repair of cervical nerve roots proximal to the root ganglia. An
751 experimental study in sheep. *The Journal of Bone and Joint Surgery*. 74, 6.
752 <https://doi.org/10.1302/0301-620X.74B6.1447258>
753

754 Hestehave S, Abelson KSP, Brønnum Pedersen T, et al. (2020) The influence of rat strain on
755 the development of neuropathic pain and comorbid anxio-depressive behaviour after nerve
756 injury. *Scientific Reports* 10, 20981. doi:10.1038/s41598-020-77640-8.
757

758 Hines TJ, Tadenev ALD, Lone MA, Hatton CL, et al. (2021) Precision mouse models of
759 Yars/dominant intermediate Charcot-Marie-Tooth disease type C and Sptlc1/hereditary
760 sensory and autonomic neuropathy type 1. *Journal of anatomy*, doi:10.1111/joa.13605
761

762 Holm IE, Alstrup AKO, Luo Y (2016) Genetically modified pig models for
763 neurodegenerative disorders. *The Journal of Pathology* 238, 267–287. doi:10.1002/path.4654.
764

765 Holz RW, Fisher SK (1999) *Synaptic Transmission*. In PhD. George J Siegel, MD, Editor-in-
766 Chief, Bernard W Agranoff, MD, R Wayne Albers, PhD, Stephen K Fisher, PhD, and

767 Michael D Uhler, ed. *Basic Neurochemistry: Molecular, Cellular and Medical Aspects*.
768 Philadelphia: Lippincott-Raven.
769

770 Hourigan ML, McKinnon NB, Johnson M, et al. (2015) Increased motor unit potential shape
771 variability across consecutive motor unit discharges in the tibialis anterior and vastus
772 medialis muscles of healthy older subjects. *Clinical Neurophysiology* 126, 2381–2389.
773 doi:10.1016/j.clinph.2015.02.002.
774

775 Iyer C, Wang X, Renusch SR, et al. (2017) SMN Blood Levels in a Porcine Model of Spinal
776 Muscular Atrophy. *JND* 4, 59–66. doi:10.3233/JND-170209.
777

778 Jahns H, Vernau KM, Nolan CM, et al. (2020) Polyneuropathy in Young Siberian Huskies
779 Caused by Degenerative and Inflammatory Diseases. *Vet Pathol* 57, 666–674.
780 doi:10.1177/0300985820934112.
781

782 Jones RA, Harrison C, Eaton SL, et al. (2017) Cellular and Molecular Anatomy of the
783 Human Neuromuscular Junction. *Cell Reports* 21, 2348–2356.
784 doi:10.1016/j.celrep.2017.11.008.
785

786 Jones RA, Reich CD, Dissanayake KN, et al. (2016) NMJ-morph reveals principal
787 components of synaptic morphology influencing structure–function relationships at the
788 neuromuscular junction. *Open Biology* 6, 160240. doi:10.1098/rsob.160240.
789

790 Jongh R, Spijkers XM, Pasteuning-Vuhman S, et al. (2021) Neuromuscular junction-on-a-
791 chip: ALS disease modeling and read-out development in microfluidic devices. *Journal of*
792 *Neurochemistry*, jnc.15289. doi:10.1111/jnc.15289.
793

794 Karbiener M, Jarvis JC, Perkins JD, et al. (2016) Reversing Age Related Changes of the
795 Laryngeal Muscles by Chronic Electrostimulation of the Recurrent Laryngeal Nerve S. E.
796 Alway, ed. *PLoS ONE* 11, e0167367. doi:10.1371/journal.pone.0167367.
797

798 Kazamel M, Dyck PJ Sensory manifestations of diabetic neuropathies: Anatomical and
799 clinical correlations. *Prosthetics and Orthotics International*, 39, 7-16.
800 doi:10.1177/0309364614536764

801 Koch TG, Berg LC, Betts DH (2009) Current and future regenerative medicine - principles,
802 concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine.
803 Can Vet J 50, 155–165.
804

805 Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal
806 degeneration in Charcot–Marie–Tooth disease type 1A. Brain: a journal of neurology, 123,
807 1516-27. doi:10.1093/brain/123.7.1516
808

809 Lanigan LG, Russell DS, Woolard KD, et al. (2021) Comparative Pathology of the Peripheral
810 Nervous System. Veterinary Pathology 58, 10–33. doi:10.1177/0300985820959231.
811

812 Lin C-Y, Yoshida M, Li L-T, et al. (2019) iPSC-derived functional human neuromuscular
813 junctions model the pathophysiology of neuromuscular diseases. JCI Insight 4.
814 doi:10.1172/jci.insight.124299.
815

816 Lin W, McArdle JJ (2021) The NMJ as a model synapse: New perspectives on synapse
817 formation, function, and maintenance. Neuroscience Letters 740, 135431.
818 doi:10.1016/j.neulet.2020.135431.
819

820 Martineau É, Di Polo A, Vande Velde C, et al. (2018) Dynamic neuromuscular remodeling
821 precedes motor-unit loss in a mouse model of ALS. eLife 7, e41973.
822 doi:10.7554/eLife.41973.
823

824 Marx A, Porubsky S, Belharazem D, et al. (2015) Thymoma related myasthenia gravis in
825 humans and potential animal models. Experimental Neurology 270, 55–65.
826 doi:10.1016/j.expneurol.2015.02.010.
827

828 Marx V (2021) Method of the Year: spatially resolved transcriptomics. Nat Methods 18, 9–
829 14. doi:10.1038/s41592-020-01033-y.
830

831 McMacken G, Whittaker RG, Charlton R, et al. (2021) Inherited neuropathies with
832 predominant upper limb involvement: genetic heterogeneity and overlapping pathologies.
833 European Journal of Neurology 1, 297-304. doi.org/10.1111/ene.14514
834

835 Millecamps S, Julien JP (2013) Axonal transport deficits and neurodegenerative diseases.
836 Nature Reviews Neuroscience 14. doi:10.1038/nrn3380.
837

838 Minty G, Hoppen A, Boehm I, et al. (2020) aNMJ-morph: a simple macro for rapid analysis
839 of neuromuscular junction morphology. Royal Society Open Science 7, 200128.
840 doi:10.1098/rsos.200128.
841

842 Mohammed HO, Divers TJ, Summers BA, et al. (2007) Vitamin E deficiency and risk of
843 equine motor neuron disease. Acta Veterinaria Scandinavica 49, 17. doi:10.1186/1751-0147-
844 49-17.
845

846 Mohs RC, Greig NH (2017) Drug discovery and development: Role of basic biological
847 research. Alzheimer's and Dementia: Translational Research and Clinical Interventions 3,
848 651–657. doi:10.1016/j.trci.2017.10.005.
849

850 Nishimune H, Shigemoto K (2018) Practical Anatomy of the Neuromuscular Junction in
851 Health and Disease. Neurol Clin 36, 231–240. doi:10.1016/j.ncl.2018.01.009.
852

853 Oda K (1984) Age changes of motor innervation and acetylcholine receptor distribution on
854 human skeletal muscle fibres. Journal of the Neurological Sciences 66, 327–338.
855 doi:10.1016/0022-510X(84)90021-2.
856

857 Ortvad KF (2018) Regenerative Medicine and Rehabilitation for Tendinous and Ligamentous
858 Injuries in Sport Horses. Veterinary Clinics of North America: Equine Practice 34, 359–373.
859 doi:10.1016/j.cveq.2018.04.012.
860

861 Paul AC (2001) Muscle length affects the architecture and pattern of innervation differently
862 in leg muscles of mouse, guinea pig, and rabbit compared to those of human and monkey
863 muscles. Anat Rec 262, 301–309. doi:10.1002/1097-0185(20010301)262:3<301::AID-
864 AR1045>3.0.CO;2-H.
865

866 Payne JH, Hogg RA, Otter A, et al. (2011) Emergence of suspected type D botulism in
867 ruminants in England and Wales (2001 to 2009), associated with exposure to broiler litter.
868 Veterinary Record, 4.

869 Pelekanos M, Leinenga G, Odabae M, et al. (2018) Establishing sheep as an experimental
870 species to validate ultrasound-mediated blood-brain barrier opening for potential therapeutic
871 interventions. *Theranostics* 8, 2583–2602. doi:10.7150/thno.22852.
872

873 Pereira JA, Gerber J, Ghidinelli M, et al. (2020) Mice carrying an analogous heterozygous
874 dynamin 2 K562E mutation that causes neuropathy in humans develop predominant
875 characteristics of a primary myopathy. *Human Molecular Genetics*, ddaa034.
876 doi:10.1093/hmg/ddaa034.
877

878 Pereira JA, Lebrun-Julien F, Suter U (2012) Molecular mechanisms regulating myelination in
879 the peripheral nervous system. *Trends in Neurosciences* 35, 123–134.
880 doi:10.1016/j.tins.2011.11.006.
881

882 Pessoa LV de F, Bressan FF, Freude KK (2019) Induced pluripotent stem cells throughout
883 the animal kingdom: Availability and applications. *World J Stem Cells* 11, 491–505.
884 doi:10.4252/wjsc.v11.i8.491.
885

886 Piasecki M, Ireland A, Stashuk D, et al. (2016) Age-related neuromuscular changes affecting
887 human vastus lateralis. *Journal of Physiology* 594, 4525–4536. doi:10.1113/JP271087.
888

889 Picher-Martel V, Valdmanis PN, Gould PV, et al. (2016) From animal models to human
890 disease: a genetic approach for personalized medicine in ALS. *acta neuropathol commun* 4,
891 70. doi:10.1186/s40478-016-0340-5.
892

893 Ribitsch I, Baptista PM, Lange-Consiglio A, et al. (2020) Large Animal Models in
894 Regenerative Medicine and Tissue Engineering: To Do or Not to Do. *Front Bioeng*
895 *Biotechnol* 8, 972–972. doi:10.3389/fbioe.2020.00972.
896

897 Rossignol F, Brandenberger O, Perkins JD, et al. (2018) Modified first or second cervical
898 nerve transplantation technique for the treatment of recurrent laryngeal neuropathy in horses.
899 *Equine Veterinary Journal* 50, 457–464. doi:10.1111/evj.12788.
900

901 Salvadori C, Tartarelli CL, Baroni M, et al. (2005) Peripheral Nerve Pathology in Two
902 Rottweilers with Neuronal Vacuolation and Spinocerebellar Degeneration. *Veterinary*
903 *Pathology* 42, 852–855. doi:10.1354/vp.42-6-852.
904

905 Salvadori C, Tartarelli CL, Baroni M, et al. (2007) Neuronal Vacuolation, Myelopathy and
906 Laryngeal Neuropathy in a Mixed-Breed Dog. *Journal of Veterinary Medicine Series A* 54,
907 445–448. doi:10.1111/j.1439-0442.2007.00936.x.
908

909 Sályi G, Glávits R, Molnár T (2000) Putative Peripheral Neuropathy in Suckling Piglets.
910 *Journal of Veterinary Medicine, Series B* 47, 401–410. doi:10.1046/j.1439-
911 0450.2000.00401.x.
912

913 Sanes JR, Lichtman JW (1999) Development of the Vertebrate Neuromuscular Junction. ,
914 389–442.
915

916 Sasaki N, Imamura Y, Sekiya A, et al. (2016) Four cases of equine motor neuron disease in
917 Japan. *J Equine Sci* 27, 119–124. doi:10.1294/jes.27.119.
918

919 Scherer SS, Wrabetz L (2008) Molecular mechanisms of inherited demyelinating
920 neuropathies. *Glia* 56, 1578–1589. doi:10.1002/glia.20751.
921

922 Seyhan AA (2019) Lost in translation: the valley of death across preclinical and clinical
923 divide – identification of problems and overcoming obstacles. *Translational Medicine*
924 *Communications* 4, 1–19. doi:10.1186/s41231-019-0050-7.
925

926 Shelton GD, Johnson GC, O'Brien DP, et al. (2012) Degenerative myelopathy associated
927 with a missense mutation in the superoxide dismutase 1 (SOD1) gene progresses to
928 peripheral neuropathy in Pembroke Welsh Corgis and Boxers. *Journal of the Neurological*
929 *Sciences* 318, 55–64. doi:10.1016/j.jns.2012.04.003.
930

931 Sisó S, Hanzlíček D, Fluehmann G, et al. (2006) Neurodegenerative diseases in domestic
932 animals: A comparative review. *The Veterinary Journal* 171, 20–38.
933 doi:10.1016/j.tvjl.2004.08.015.

934 Skedsmo FS, Espenes A, Tranulis MA, et al. (2021) Impaired NDRG1 functions in Schwann
935 cells cause demyelinating neuropathy in a dog model of Charcot-Marie-Tooth type 4D.
936 Neuromuscular Disorders 31, 56–68. doi:10.1016/j.nmd.2020.11.010.
937

938 Skedsmo FS, Malachin G, Våge DI, et al. (2020) Demyelinating polyneuropathy in goats
939 lacking prion protein. The FASEB Journal 34, 2359–2375. doi:10.1096/fj.201902588R.
940

941 Slater CR (2015) The functional organization of motor nerve terminals. Progress in
942 Neurobiology 134, 55–103. doi:10.1016/j.pneurobio.2015.09.004.
943

944 Slater CR (2017) The structure of human neuromuscular junctions: Some unanswered
945 molecular questions. International Journal of Molecular Sciences 18.
946 doi:10.3390/ijms18102183.
947

948 Slater CR (2019) ‘Fragmentation’ of NMJs: a sign of degeneration or regeneration? A long
949 journey with many junctions. Neuroscience 439, 28–40.
950 doi:10.1016/j.neuroscience.2019.05.017.
951

952 Sleigh JN, Mech AM, Schiavo G (2020) Developmental demands contribute to early
953 neuromuscular degeneration in CMT2D mice. Cell Death and Disease 11.
954 doi:10.1038/s41419-020-02798-y.
955

956 Smith RK, Garvican ER, Fortier LA (2014) The current ‘state of play’ of regenerative
957 medicine in horses: what the horse can tell the human. Regenerative Medicine 9, 673–685.
958 doi:10.2217/rme.14.42.
959

960 Sousa RFA, Almeida VM, Neto JE, et al. (2016) Laryngeal Neuropathy in Adult Goats With
961 Copper Deficiency. doi:10.1177/0300985816681410.
962

963 Starritt NE, Kettle SAJ, Glasby MA (2011) Sutureless repair of the facial nerve using
964 biodegradable glass fabric. The Laryngoscope. 8, 1614-1619.
965 <https://doi.org/10.1002/lary.21868>
966

967 Sullivan JM, Motley WW, Johnson JO, et al. (2020) Dominant mutations of the Notch ligand
968 Jagged1 cause peripheral neuropathy. *Journal of Clinical Investigation* 130, 1506–1512.
969 doi:10.1172/JCI128152.
970

971 Thompson SR, Wishart TM, Patani R, et al. (2012) Using induced pluripotent stem cells
972 (iPSC) to model human neuromuscular connectivity: promise or reality? *Journal of Anatomy*
973 2, 122-30. doi: 10.1111/j.1469-7580.2011.01459.x.
974

975 Tintignac LA, Brenner HR, Rüegg MA (2015) Mechanisms regulating neuromuscular
976 junction development and function and causes of muscle wasting. *Physiological Reviews* 95,
977 809–852. doi:10.1152/physrev.00033.2014.
978

979 Travillian RS, Rosse C, Shapiro LG (2003) An approach to the anatomical correlation of
980 species through the Foundational Model of Anatomy. *AMIA . Annual Symposium*
981 *proceedings AMIA Symposium*, 669–73.
982

983 Uzal FA, Mukai M, Woods L, et al. (2012) Acute respiratory distress in an alpaca. *Veterinary*
984 *pathology* 49, 1070–3. doi:10.1177/0300985812447825.
985

986 Valdez G, Tapia JC, Kang H, et al. (2010) Attenuation of age-related changes in mouse
987 neuromuscular synapses by caloric restriction and exercise. *Proceedings of the National*
988 *Academy of Sciences* 107, 14863–14868. doi:10.1073/pnas.1002220107.
989

990 Wang GD, Zhai W, Yang HC, et al. (2013) The genomics of selection in dogs and the
991 parallel evolution between dogs and humans. *Nature Communications* 4.
992 doi:10.1038/ncomms2814.
993

994 Weber K, Pearce DA (2013) Large Animal Models for Batten Disease: A Review. *J Child*
995 *Neurol* 28, 1123–1127. doi:10.1177/0883073813493666.
996

997 Wernig A, Herrera AA (1986) Sprouting and remodelling at the nerve-muscle junction.
998 *Progress in Neurobiology* 27, 251–291. doi:10.1016/0301-0082(86)90023-7.

999 Wohlsein P, Brüggemann M, Pfeiffer I, et al. (2012) Spontaneous degenerative
1000 polioencephalomyelopathy in feeder pigs--a new motor neuron disease? *Berliner und*
1001 *Munchener tierärztliche Wochenschrift* 125, 520–8.
1002
1003 Wood SJ, Slater CR (2001) Safety factor at the neuromuscular junction. *Progress in*
1004 *Neurobiology* 64, 393–429.
1005
1006 Xia C, Fan J, Emanuel G, et al. (2019) Spatial transcriptome profiling by MERFISH reveals
1007 subcellular RNA compartmentalization and cell cycle-dependent gene expression. *Proc Natl*
1008 *Acad Sci USA* 116, 19490–19499. doi:10.1073/pnas.1912459116.
1009
1010 Yan S, Tu Z, Liu Z, et al. (2018) A Huntingtin Knockin Pig Model Recapitulates Features of
1011 Selective Neurodegeneration in Huntington's Disease. *Cell* vol. 4, 989-1002
1012 doi:10.1016/j.cell.2018.03.005
1013
1014 Yang W, Chen X, et al. (2021) Genetically modified large animal models for investigating
1015 neurodegenerative diseases. *Cell Biosci* 11, 218. <https://doi.org/10.1186/s13578-021-00729-8>
1016
1017 Yang H, Wang G, et al. (2014) Species-dependent neuropathology in transgenic SOD1 pigs.
1018 *Cell Res* 24, 464–481. <https://doi.org/10.1038/cr.2014.25>
1019
1020 Yaron A, Schuldiner O (2016) Common and Divergent Mechanisms in Developmental
1021 Neuronal Remodeling and Dying Back Neurodegeneration. *Current Biology* 26, R628–R639.
1022 doi:10.1016/j.cub.2016.05.025.
1023
1024 Zakrzewski W, Dobrzyński M, Szymonowicz M, et al. (2019) Stem cells: past, present, and
1025 future. *Stem Cell Res Ther* 10, 68 <https://doi.org/10.1186/s13287-019-1165-5>
1026
1027 Zambon AA, Natali Sora MG, Cantarella G, et al. (2017) Vocal cord paralysis in Charcot–
1028 Marie–Tooth type 4b1 disease associated with a novel mutation in the myotubularin-related
1029 protein 2 gene: A case report and review of the literature. *Neuromuscular Disorders* 27, 487–
1030 491. doi:10.1016/j.nmd.2017.01.006.

1031 Zou S, Pan BX (2022) Post-synaptic specialization of the neuromuscular junction: junctional
1032 folds formation, function, and disorders. Cell Biosci 12, 93 [https://doi.org/10.1186/s13578-](https://doi.org/10.1186/s13578-022-00829-z)
1033 [022-00829-z](https://doi.org/10.1186/s13578-022-00829-z)

1034

1035

1036 **Data Sharing:** The data that support the findings within this review are openly available at
1037 https://github.com/Boehmin/NMJ_analysis.git

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047 Figure 1: A schematic diagram of the healthy motor axon.

1048

1049 Figure 2: A schematic diagram of the unhealthy motor axon.

1050

1051

1052

1053 Figure 3: Heterogeneity of the mammalian NMJ

1054 Confocal micrographs representing average NMJ morphology in *soleus*, a predominantly
1055 slow-twitch pelvic/hind/lower limb muscle, across mammalian species arranged in ascending
1056 body size: the mouse, sheep, pig, human and pony. The upper panel depicts composite
1057 images of pre- (cyan) and post-synapse (magenta), pseudo-coloured in Fiji. The bottom
1058 panels depict the pre- and post-synapse individually in greyscale.

1059 SV2 = synaptic vesicle protein 2 (cyan); 2H3 and 3A10 = neurofilament (cyan); α -BTX (α -
1060 bungarotoxin) = acetylcholine receptors (magenta);

1061 Scale bar = 10 μ m across all images.

1062

1063 Figure 4: Evolutionary divergence of large mammalian models in comparison to mouse and
1064 human

1065 (A) Phylogenetic tree depicting the timeline of divergence in million years ago (MYA)
1066 between mouse and human (both part of the superorder Euarchontoglires), sheep and
1067 pig (both part of the order Artiodactyla) and pony (all three part of the superorder
1068 Laurasiatheria). It is evident that despite mouse and human sharing the same clade,
1069 they diverged many million years sooner than the here listed domestic animals.
1070 Phylogenetic tree generated on <http://www.timetree.org>.

1071 (B) This so-called tanglegram showcases the difference between two dendrograms. In this
1072 case, the individual dendrograms depict pre- and post-synaptic components of the
1073 NMJ. Comparison via such a tanglegram allows to assess the differences or
1074 similarities between species, across pre-synaptic, or post-synaptic components of the
1075 NMJ. Both dendrograms showcase clustering of species according to the similarity in
1076 post-synaptic (left dendrogram) or pre-synaptic (right dendrogram) NMJ variables
1077 and their associated and derived variables resulting from analysis with NMJ-
1078 morph/aNMJ-morph (Jones *et al.*, 2016; Minty *et al.*, 2020). Red lines indicate
1079 similarities in subtree branches: the mouse is most different from the other species in
1080 post- and pre-synaptic morphology. Thick black lines at the edges of the dendrogram
1081 indicate differences in branch distance from their node of origin: whilst sheep and
1082 human are most similar in their post-synaptic morphology, the sheep and pony are
1083 most similar in their pre-synaptic morphology.

1084 Mouse and human data were reproduced from (Jones *et al.*, 2017). Sheep and pig data
1085 were reproduced from (Boehm *et al.*, 2020). Pony data yet unpublished (Cahalan *et*
1086 *al.*, 2022, under review). Tanglegram was generated in RStudio (version 1.4.0) using
1087 the packages tidverse, usedist, vegan, magrittr and dendextend (Galili, 2015).